Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia

Abstract

The International Society for CNS Clinical Trials and Methodology (ISCTM) Adaptive Design Working Group (IADWG) designed a case study simulation exercise to compare the value of traditional versus adaptive design approaches to phase II clinical trial design in schizophrenia in statistical and economic terms. Operational characteristics of both designs were compared across 7 likely dose-response curves. Based on IADWG members’ recent research experience in schizophrenia, estimates of expected net present value (eNPV) for the molecule were compared for the traditional and adaptive designs. Across dose-response curve scenarios with a minimum effective dose (MED), the adaptive design was more likely to show proof of concept and correctly identify the MED than was the traditional design. Even with a conservative weighting of possible dose-response curves, using an adaptive design in phase II resulted in higher eNPV. This simulation supports the statistical and economic value for decision makers exploring the use of adaptive approaches to phase II research in schizophrenia.

Keywords

adaptive dose response schizophrenia net present value minimum effective dose

Get full access to this article

View all access options for this article.

References

Bornkamp

Bretz

Dmitrienko

. Innovative approaches for designing and analyzing adaptive dose-ranging trials (with discussion). J Biopharm Stat. 2007;17:965–995.

Dragalin

Bornkamp

Bretz

. A simulation study to compare new adaptive dose-ranging designs. Stat Biopharm Res. 2010;2(4):487–512.

Kalali

Preskorn

Kwentus

Stahl

. Essential CNS Drug Development. Cambridge, UK: Cambridge University Press; 2012.

Citrome

. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123(2):153–162.

Antonijevic

Pinheiro

Fardipour

Lewis

. Impact of dose selection strategies used in phase II on the probability of success in phase III. Stat Biopharm Res. 2010;2(4):469–486.

West

Harrison

. Bayesian Forecasting and Dynamic Models. New York, NY: Springer-Verlag; 1997.

Shen

Preskorn

Dragalin

. How adaptive trial designs can increase efficiency in psychiatric drug development: a case study. Innov Clin Neurosci. 2011;8:26–34.

Food and Drug Administration. Guidance for industry. Adaptive design clinical trials for drugs and biologics. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Published February 2010.